Browse the latest research summaries in the field of pain management for spinal cord injury patients and caregivers.
Showing 211-220 of 682 results
Frontiers in Behavioral Neuroscience, 2023 • April 4, 2023
This study aimed to explore the effect of tDCS on neuropathic pain induced by SCI and its underlying mechanism, focusing on the role of microglia and cytokines. The results indicate that tDCS can effe...
KEY FINDING: tDCS treatment improved thermal withdrawal threshold and motor function in SCI rats compared to the vehicle group.
Pain Ther, 2023 • April 28, 2023
This multinational, open-label study assessed the long-term safety and efficacy of mirogabalin for central neuropathic pain (CNeP) in Asian patients with spinal cord injury (CNePSCI), Parkinson's dise...
KEY FINDING: Mirogabalin was generally safe and well-tolerated, with common side effects including somnolence, peripheral edema, edema, and dizziness, most of which were mild.
Trials, 2023 • June 5, 2023
This study protocol outlines a prospective, single-center, open-label, randomized, two-way crossover trial to investigate the efficacy of differential target multiplexed (DTM) spinal cord stimulation ...
KEY FINDING: The primary outcome will be the rate of pain improvement, defined as a 33% or greater reduction in pain scores, three months after SCS system implantation.
Journal of Inflammation Research, 2023 • June 13, 2023
This review highlights the significant role of non-coding RNAs (ncRNAs) in regulating neuroinflammation (NI) following spinal cord injury (SCI), which subsequently influences the development of neurop...
KEY FINDING: miRNAs regulate inflammation after SCI by influencing microglia-mediated inflammation, with some miRNAs like miR-137-3p reducing pro-inflammatory factors by targeting NeuroD1. NF-κB-dependent inflammation is also modulated by miRNAs, impacting neuropathic nociceptive hyperalgesia.
J Pain, 2023 • November 1, 2023
The study aimed to identify variables that moderate treatment response to four psychological pain interventions: cognitive therapy (CT), hypnosis (HYP), hypnosis focused on changing pain-related cogni...
KEY FINDING: Higher hypnotizability was associated with better outcomes in depressive symptoms for those who received hypnosis and hypnotic cognitive therapy.
The Journal of Spinal Cord Medicine, 2024 • May 31, 2023
This systematic review assessed the efficacy of various strategies for treating pain interference in individuals with neuropathic pain following spinal cord injury. Moderate to high quality studies sh...
KEY FINDING: Pregabalin and gabapentin were shown to have a beneficial effect on sleep interference.
The Journal of Spinal Cord Medicine, 2024 • January 1, 2024
The study assessed the occurrence and characteristics of neuropathic pain in 104 patients with traumatic spinal cord injury (SCI). The results indicated that 74% of patients experienced neuropathic pa...
KEY FINDING: Neuropathic pain was present in 74% of the spinal cord injury patients studied.
J. Clin. Med., 2023 • July 7, 2023
This case study describes the adaptation and implementation of hypnotic cognitive therapy (HYP-CT) intervention for early SCI pain in the context of mechanical ventilation dependence and weaning. The ...
KEY FINDING: The participant reported immediate reductions in pain intensity following each intervention session.
Int. J. Mol. Sci., 2023 • July 5, 2023
This research evaluates the feasibility of a multimodal pain assessment protocol during rehabilitation following spinal cord injury (SCI). The protocol amalgamates clinical workup (CW), quantitative s...
KEY FINDING: The SCI Pain Instrument (SCIPI) was efficient in distinguishing between nociceptive and neuropathic pain, showing a progressive increase in severity over time.
Pain, 2024 • January 1, 2024
This study demonstrates that drug-free PLG nanoparticles can effectively reduce neuropathic pain following spinal cord injury (SCI) in mice. The nanoparticles work by modulating the immune response, p...
KEY FINDING: Acute treatment with PLG nanoparticles following thoracic SCI significantly reduces tactile and cold hypersensitivity scores in a durable fashion.